Study of Oral AEE788 in Adults With Advanced Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
AEE788 is an orally active, reversible, small-molecule, multi-targeted kinase inhibitor with
potent inhibitory activity against ErbB and VEGF receptor family of tyrosine kinases. It has
an IC50 of less than 100 nM against p-EGFR, p-ErbB2, and p-KDR (VEGFR2). This study will
assess the safety, pharmacokinetic (PK)/pharmacodynamic (PD) profiles and clinical activity
of AEE788 in advanced cancers.